[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 26 of about 26
1. Caudle AS, Gonzalez-Angulo AM, Hunt KK, Liu P, Pusztai L, Symmans WF, Kuerer HM, Mittendorf EA, Hortobagyi GN, Meric-Bernstam F: Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. J Clin Oncol; 2010 Apr 10;28(11):1821-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer.
  • PURPOSE Although most breast cancer patients who receive neoadjuvant chemotherapy (NCT) have a tumor response, a small proportion experience progressive disease (PD).
  • We sought to identify predictors of tumor progression during NCT with the ultimate aim of identifying patients who might benefit from a first-line surgical approach or from novel targeted therapies.
  • PATIENTS AND METHODS Data were obtained from reviewing medical records of patients with stage I to III breast cancer who received NCT (anthracycline and/or taxane based).
  • Factors predictive of PD included African American race (P = .002), tumor (T) status (P = .002), and American Joint Committee on Cancer clinical stage (P = .02).
  • CONCLUSION Factors predictive of PD include race, advanced tumor stage, high nuclear grade, high Ki-67 score, and ER/PR negativity.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2002 Apr 3;94(7):490-6 [11929949.001]
  • [Cites] J Clin Oncol. 2009 Jan 10;27(2):220-6 [19047281.001]
  • [Cites] Br J Cancer. 2003 Feb 10;88(3):406-12 [12569384.001]
  • [Cites] Lancet. 2003 Aug 2;362(9381):362-9 [12907009.001]
  • [Cites] N Engl J Med. 1993 Jul 29;329(5):326-31 [8321261.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2672-85 [9704717.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):460-9 [10080586.001]
  • [Cites] Ann Surg. 1999 Jul;230(1):72-8 [10400039.001]
  • [Cites] N Engl J Med. 2004 Dec 30;351(27):2817-26 [15591335.001]
  • [Cites] J Clin Oncol. 2005 Jun 1;23(16):3676-85 [15738535.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Br J Cancer. 2000 Dec;83(11):1480-7 [11076657.001]
  • [Cites] J Clin Oncol. 2001 Nov 15;19(22):4224-37 [11709566.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5678-85 [16115903.001]
  • [Cites] J Clin Oncol. 2005 Oct 10;23(29):7265-77 [16145055.001]
  • [Cites] J Clin Oncol. 2006 Mar 1;24(7):1037-44 [16505422.001]
  • [Cites] J Clin Oncol. 2006 Apr 20;24(12):1839-45 [16622258.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):2019-27 [16606972.001]
  • [Cites] JAMA. 2006 Jun 7;295(21):2492-502 [16757721.001]
  • [Cites] J Clin Oncol. 2006 Sep 10;24(26):4236-44 [16896004.001]
  • [Cites] Clin Chem. 2007 Jun;53(6):1084-91 [17463177.001]
  • [Cites] Cancer. 2007 May 1;109(9):1721-8 [17387718.001]
  • [Cites] J Clin Oncol. 2007 Oct 1;25(28):4414-22 [17785706.001]
  • [Cites] J Clin Oncol. 2008 Jan 10;26(2):246-52 [18056680.001]
  • [Cites] JAMA. 2008 Apr 2;299(13):1574-87 [18387932.001]
  • [Cites] Breast Cancer Res. 2008;10(3):R45 [18474099.001]
  • [Cites] Clin Cancer Res. 2008 Dec 15;14(24):8019-26 [19088018.001]
  • [Cites] N Engl J Med. 2002 Dec 19;347(25):1999-2009 [12490681.001]
  • (PMID = 20231683.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / T32 CA009599; United States / NCI NIH HHS / CA / T32 CA09599
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Bridged Compounds; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / Taxoids; 1605-68-1 / taxane
  • [Other-IDs] NLM/ PMC2860366
  •  go-up   go-down


2. Mazouni C, Hall A, Broglio K, Fritsche H, Andre F, Esteva FJ, Hortobagyi GN, Buzdar AU, Pusztai L, Cristofanilli M: Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy. Cancer; 2007 Feb 1;109(3):496-501
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy.
  • BACKGROUND: The purpose of the study was to determine the utility of quantitation of the extracellular domain (ECD) of the HER-2/neu receptor in the serum for predicting response to treatment in patients with primary breast cancer receiving neoadjuvant therapy.
  • METHODS: HER-2/neu ECD was measured in sera obtained from 39 patients with HER-2-amplified stage II-III primary breast cancer undergoing neoadjuvant chemotherapy.
  • Patients were randomly assigned to either 4 cycles of paclitaxel followed by 4 cycles of fluorouracil, epirubicin, and cyclophosphamide (FEC) (n = 10) or to the same chemotherapy with simultaneous weekly trastuzumab for 24 weeks (n = 29).
  • Changes in HER-2 ECD were monitored with the Bayer HER-2/neu assay over 6 months and correlated with pathological response to treatment.
  • RESULTS: Before initiation of chemotherapy, 28.2% of patients had elevated concentration of the HER-2 ECD (>15 ng/mL).
  • A decrease in the median HER-2 ECD levels from baseline to Week 3 and from baseline to Week 6 of chemotherapy was seen regardless of treatment regimen.
  • However, a 9% drop from Week 3 to Week 6 after initial chemotherapy was predictive of pCR (P = .04).
  • CONCLUSION: A decrease in serum HER-2 ECD levels early during treatment was associated with pathological response in patients receiving primary chemotherapy, particularly trastuzumab-based regimens.
  • Serum HER-2 ECD levels may serve to monitor neoadjuvant therapy in HER-2-positive primary breast cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Receptor, ErbB-2 / blood
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Biomarkers, Tumor / blood. Carcinoma, Ductal, Breast / blood. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Lobular / blood. Carcinoma, Lobular / drug therapy. Cyclophosphamide / administration & dosage. Epirubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Kinetics. Middle Aged. Neoadjuvant Therapy. Prognosis. Prospective Studies. Trastuzumab

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Trastuzumab .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 American Cancer Society.
  • (PMID = 17149760.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Biomarkers, Tumor; 3Z8479ZZ5X / Epirubicin; 8N3DW7272P / Cyclophosphamide; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab; U3P01618RT / Fluorouracil
  •  go-up   go-down


3. Ugnat AM, Xie L, Morriss J, Semenciw R, Mao Y: Survival of women with breast cancer in Ottawa, Canada: variation with age, stage, histology, grade and treatment. Br J Cancer; 2004 Mar 22;90(6):1138-43
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival of women with breast cancer in Ottawa, Canada: variation with age, stage, histology, grade and treatment.
  • This study examined the 5-year survival of 2192 breast cancer women diagnosed between 1994 and 1997 in Ottawa, Canada, by age, TNM stage, histology, grade and treatment, including assessment of the independent value of variables in defining prognosis.
  • Our results showed that age, stage, treatment and grade significantly influenced outcome regardless of the confounding factors considered, with histology failing to achieve significant independent prognostic information.
  • The survival rates were highest at ages 50-69 years for stage I and at ages 40-49 years for stages II-IV.
  • The rates were lowest at ages <or=39 years for stages I-II and at ages >or=70 years for stages III-IV.
  • The differences in survival between grade 1 and grade 3 were 9% in stage I and 20% in stage II.
  • The treatment leading to the best survival was surgery plus radiation for stages I-II and surgery combined with chemotherapy for stages III-IV.
  • Lobular carcinoma had a better prognosis than ductal carcinoma; this can be explained by more grade 1 and less grade 3 cases in lobular carcinoma.
  • Stage I patients aged 50-69 years having the best survival is likely due to the earlier diagnosis achieved through screening.
  • [MeSH-minor] Adult. Age Factors. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Histology. Humans. Middle Aged. Multivariate Analysis. Ontario / epidemiology. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Jan 15;88(2):369-74 [10640970.001]
  • [Cites] Stat Med. 1997 Jul 15;16(13):1435-49 [9249917.001]
  • [Cites] Tumori. 2000 Mar-Apr;86(2):119-23 [10855847.001]
  • [Cites] J Surg Oncol. 2000 Aug;74(4):267-72 [10962458.001]
  • [Cites] J Natl Cancer Inst. 1982 Aug;69(2):349-55 [6955542.001]
  • [Cites] Stat Med. 1990 May;9(5):529-38 [2349404.001]
  • [Cites] CMAJ. 1992 Nov 15;147(10):1477-88 [1423088.001]
  • [Cites] J Natl Cancer Inst Monogr. 1994;(16):35-42 [7999467.001]
  • [Cites] Cancer. 1995 Jan 1;75(1 Suppl):406-21 [8001011.001]
  • [Cites] Int J Cancer. 1995 Jul 17;62(2):138-44 [7622286.001]
  • [Cites] Cancer. 1996 Jan 1;77(1):97-103 [8630946.001]
  • [Cites] Tumori. 1996 Sep-Oct;82(5):441-3 [9063519.001]
  • [Cites] Eur J Cancer. 1997 Mar;33(3):425-8 [9155527.001]
  • [Cites] Aust N Z J Public Health. 1997 Apr;21(2):199-205 [9161078.001]
  • [Cites] J Am Coll Surg. 2000 May;190(5):523-9 [10801018.001]
  • (PMID = 15026792.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2409653
  •  go-up   go-down


Advertisement
4. Olson JA Jr, Budd GT, Carey LA, Harris LA, Esserman LJ, Fleming GF, Marcom PK, Leight GS Jr, Giuntoli T, Commean P, Bae K, Luo J, Ellis MJ: Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial. J Am Coll Surg; 2009 May;208(5):906-14; discussion 915-6
Hazardous Substances Data Bank. LETROZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial.
  • BACKGROUND: Neoadjuvant aromatase inhibitor therapy has been reported to improve surgical outcomes for postmenopausal women with clinical stage II or III hormone receptor-positive breast cancer.
  • RESULTS: One hundred six patients were eligible for primary analysis, 96 underwent operations, 7 received chemotherapy after progressive disease, and 3 did not undergo an operation.
  • [MeSH-major] Aromatase Inhibitors / administration & dosage. Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Lobular / drug therapy. Neoadjuvant Therapy. Nitriles / administration & dosage. Triazoles / administration & dosage
  • [MeSH-minor] Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. Humans. Mastectomy, Segmental. Middle Aged. Multivariate Analysis. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1957 Sep-Oct;10(5):1055-75 [13472656.001]
  • [Cites] Clin Cancer Res. 2004 Oct 1;10(19):6622-8 [15475452.001]
  • [Cites] Endocr Relat Cancer. 2004 Mar;11(1):85-96 [15027887.001]
  • [Cites] Ann Oncol. 2001 Nov;12(11):1527-32 [11822750.001]
  • [Cites] J Natl Cancer Inst Monogr. 2001;(30):96-102 [11773300.001]
  • [Cites] IEEE Trans Med Imaging. 2001 Sep;20(9):854-67 [11585203.001]
  • [Cites] Cancer Control. 2000 Nov-Dec;7(6):557-62 [11088064.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2229-35 [10873072.001]
  • [Cites] Cancer. 2000 May 1;88(9):2054-60 [10813717.001]
  • [Cites] J Natl Cancer Inst. 2008 Oct 1;100(19):1380-8 [18812550.001]
  • [Cites] J Clin Oncol. 2008 Feb 10;26(5):778-85 [18258986.001]
  • [Cites] Semin Oncol. 2006 Dec;33(6):650-6 [17145344.001]
  • [Cites] Cancer. 2006 May 15;106(10):2095-103 [16598749.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):2019-27 [16606972.001]
  • [Cites] Ann Surg. 2006 Feb;243(2):257-64 [16432360.001]
  • [Cites] Radiology. 2004 Dec;233(3):830-49 [15486214.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5108-16 [15998903.001]
  • [Cites] Lancet. 2005 May 14-20;365(9472):1687-717 [15894097.001]
  • [Cites] Lancet. 2005 Jan 1-7;365(9453):60-2 [15639680.001]
  • (PMID = 19476859.001).
  • [ISSN] 1879-1190
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA068438; United States / NCI NIH HHS / CA / R01 CA095614; United States / NIGMS NIH HHS / GM / U19 GM061388; United States / NCI NIH HHS / CA / 3P50 CA68438-07S2
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aromatase Inhibitors; 0 / Nitriles; 0 / Triazoles; 7LKK855W8I / letrozole
  • [Other-IDs] NLM/ NIHMS460618; NLM/ PMC3683862
  •  go-up   go-down


5. Zeeneldin AA, Mohamed AM, Abdel HA, Taha FM, Goda IA, Abodeef WT: Survival effects of cyclooxygenase-2 and 12-lipooxygenase in Egyptian women with operable breast cancer. Indian J Cancer; 2009 Jan-Mar;46(1):54-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sections from BC and nearby normal tissues were examined for expression of COX-2 and 12-LOX using reverse transcriptase polymerase chain reaction.
  • Stage II and III disease represented 25 and 75% respectively.
  • Adjuvant chemotherapy, radiotherapy and tamoxifen were used in 90, 75 and 60% respectively.
  • Patients with higher TNM stage or who developed visceral metastases had significantly higher COX-2 expression.
  • [MeSH-major] Arachidonate 12-Lipoxygenase / metabolism. Breast Neoplasms / enzymology. Carcinoma, Ductal, Breast / enzymology. Carcinoma, Lobular / enzymology. Cyclooxygenase 2 / metabolism
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Egypt. Female. Humans. Immunoenzyme Techniques. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19282568.001).
  • [ISSN] 0019-509X
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] EC 1.13.11.31 / Arachidonate 12-Lipoxygenase; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


6. Beadle BM, Woodward WA, Tucker SL, Outlaw ED, Allen PK, Oh JL, Strom EA, Perkins GH, Tereffe W, Yu TK, Meric-Bernstam F, Litton JK, Buchholz TA: Ten-year recurrence rates in young women with breast cancer by locoregional treatment approach. Int J Radiat Oncol Biol Phys; 2009 Mar 1;73(3):734-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ten-year recurrence rates in young women with breast cancer by locoregional treatment approach.
  • The goal of this study is to determine the impact of locoregional treatment strategy, breast-conserving therapy (BCT), mastectomy alone (M), or mastectomy with adjuvant radiation (MXRT), on LRR for patients 35 years or younger.
  • METHODS AND MATERIALS: Data for 668 breast cancers in 652 young patients with breast cancer were retrospectively reviewed; 197 patients were treated with BCT, 237 with M, and 234 with MXRT.
  • In the entire cohort, 10-year actuarial LRR rates varied by locoregional treatment: 19.8% for BCT, 24.1% for M, and 15.1% for MXRT (p = 0.05).
  • In patients with Stage II disease, 10-year actuarial LRR rates by locoregional treatment strategy were 17.7% for BCT, 22.8% for M, and 5.7% for MXRT (p = 0.02).
  • On multivariate analysis, M (hazard ratio, 4.45) and Grade III disease (hazard ratio, 2.24) predicted for increased LRR.
  • In patients with Stage I disease, there was no difference in LRR rates based on locoregional treatment (18.0% for BCT, 19.8% for M; p = 0.56), but chemotherapy use had a statistically significant LRR benefit (13.5% for chemotherapy, 27.9% for none; p = 0.04).
  • CONCLUSIONS: Young women have high rates of LRR after breast cancer treatment.
  • For patients with Stage II disease, the best locoregional control rates were achieved with MXRT.
  • For patients with Stage I disease, similar outcomes were achieved with BCT and mastectomy; however, chemotherapy provided a significant benefit to either approach.

  • Genetic Alliance. consumer health - TEN.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1688-97 [11250998.001]
  • [Cites] Cancer. 2007 May 15;109(10):1957-64 [17394192.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Jan;14(1):3-10 [3335459.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Apr;14(4):659-63 [3350720.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Aug;15(2):271-6 [3403310.001]
  • [Cites] Helv Chir Acta. 1989 Apr;55(6):837-42 [2753724.001]
  • [Cites] J Clin Oncol. 1990 Apr;8(4):591-8 [2313329.001]
  • [Cites] Lancet. 1993 Apr 24;341(8852):1039-43 [8096955.001]
  • [Cites] J Clin Oncol. 1994 May;12(5):888-94 [8164038.001]
  • [Cites] J Natl Cancer Inst Monogr. 1994;(16):35-42 [7999467.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Feb 15;31(4):765-75 [7860387.001]
  • [Cites] J Natl Cancer Inst. 1996 Nov 20;88(22):1659-64 [8931610.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Mar 1;40(4):859-67 [9531371.001]
  • [Cites] J Am Coll Surg. 1998 Jul;187(1):1-8 [9660018.001]
  • [Cites] Lancet. 2005 Dec 17;366(9503):2087-106 [16360786.001]
  • [Cites] Eur J Cancer. 2006 Feb;42(3):351-6 [16314086.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Aug 1;65(5):1345-52 [16750315.001]
  • [Cites] Clin Plast Surg. 2007 Jan;34(1):29-37; abstract v-vi [17307069.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Apr 1;67(5):1282-90 [17275207.001]
  • [Cites] Plast Reconstr Surg. 2004 Sep 15;114(4):950-60 [15468404.001]
  • (PMID = 18707822.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / KL2 RR024149-01; None / None / / KL2 RR024149-02; None / None / / KL2 RR024149-01; United States / NCRR NIH HHS / RR / KL2 RR024149; United States / NCRR NIH HHS / RR / KL2 RR024149-02
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS269607; NLM/ PMC3041273
  •  go-up   go-down


7. Cristofanilli M, Gonzalez-Angulo A, Sneige N, Kau SW, Broglio K, Theriault RL, Valero V, Buzdar AU, Kuerer H, Buchholz TA, Hortobagyi GN: Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol; 2005 Jan 1;23(1):41-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes.
  • PURPOSE: To investigate the impact of histologic type invasive lobular carcinoma (ILC) versus invasive ductal carcinoma (IDC) on response to primary chemotherapy (PC) and long-term outcome.
  • PATIENTS AND METHODS: The study included 1,034 patients with stage II and III breast cancer who participated in six clinical trials of PC at our institution between 1985 and 2002.
  • Patients with ILC tended to be older (median age, 53 years v 47 years for patients with IDC) and have more hormone-receptor-positive tumors (92% v 62%; P < .001), lower nuclear grade (nuclear grade 3, 16% v 56%; P < .001), and higher stage at diagnosis (10% v 0% with stage IIIB or IIIC disease; P < .001).
  • At a median follow-up time of 70 months, ILC patients tended to have longer recurrence-free survival (P = .004) and overall survival (P = .001).
  • [MeSH-major] Breast Neoplasms / drug therapy. Breast Neoplasms / mortality. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / mortality
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Axilla. Bridged Compounds / therapeutic use. Carcinoma, Ductal / drug therapy. Carcinoma, Ductal / mortality. Carcinoma, Ductal / pathology. Disease-Free Survival. Humans. Lymph Nodes / pathology. Middle Aged. Neoplasms, Hormone-Dependent / drug therapy. Neoplasms, Hormone-Dependent / mortality. Taxoids / therapeutic use. Treatment Outcome

  • Genetic Alliance. consumer health - Invasive lobular carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2005 Sep 20;23(27):6796; author reply 6796-7 [16170189.001]
  • [ErratumIn] J Clin Oncol. 2013 Aug 10;31(23):2977. Buccholz, Thomas A [corrected to Buchholz, Thomas A]
  • (PMID = 15625359.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bridged Compounds; 0 / Taxoids; 1605-68-1 / taxane
  •  go-up   go-down


8. Cohen LF, Breslin TM, Kuerer HM, Ross MI, Hunt KK, Sahin AA: Identification and evaluation of axillary sentinel lymph nodes in patients with breast carcinoma treated with neoadjuvant chemotherapy. Am J Surg Pathol; 2000 Sep;24(9):1266-72
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification and evaluation of axillary sentinel lymph nodes in patients with breast carcinoma treated with neoadjuvant chemotherapy.
  • Sentinel lymph node (SLN) biopsy has been shown to predict axillary metastases accurately in early stage breast cancer.
  • Some patients with locally advanced breast cancer receive preoperative (neoadjuvant) chemotherapy, which may alter lymphatic drainage and lymph node structure.
  • In this study, we examined the feasibility and accuracy of SLN mapping in these patients and whether serial sectioning and keratin immunohistochemical (IHC) staining would improve the identification of metastases in lymph nodes with chemotherapy-induced changes.
  • Thirty-eight patients with stage II or III breast cancer treated with neoadjuvant chemotherapy were included.
  • Our findings indicate that lymph node mapping in patients with breast cancer treated with neoadjuvant chemotherapy can identify the SLN, and SLN biopsy in this group accurately predicts axillary nodal status in most patients.
  • Furthermore, serial sectioning and IHC staining aid in the identification of occult micrometastases in lymph nodes with chemotherapy-induced changes.
  • [MeSH-major] Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Carcinoma / drug therapy. Carcinoma / pathology. Lymph Nodes / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Axilla. Biopsy, Needle. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / surgery. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / pathology. Carcinoma, Lobular / surgery. Female. Humans. Immunohistochemistry. Keratins / analysis. Lymph Node Excision. Lymphatic Metastasis. Microtomy. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10976701.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 68238-35-7 / Keratins
  •  go-up   go-down


9. Aukema TS, Straver ME, Peeters MJ, Russell NS, Gilhuijs KG, Vogel WV, Rutgers EJ, Olmos RA: Detection of extra-axillary lymph node involvement with FDG PET/CT in patients with stage II-III breast cancer. Eur J Cancer; 2010 Dec;46(18):3205-10
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of extra-axillary lymph node involvement with FDG PET/CT in patients with stage II-III breast cancer.
  • PURPOSE: The aim of this prospective study was to assess the incidence of extra-axillary lymph node involvement on baseline FDG PET/CT in patients with stage II-III breast cancer scheduled for neo-adjuvant chemotherapy.
  • METHODS: Patients with invasive breast cancer of >3 cm and/or proven axillary lymph node metastasis were included for before neo-adjuvant chemotherapy.
  • Radiotherapy treatment was altered in 7 patients with extra-axillary involvement (12% of the total group).
  • CONCLUSIONS: FDG PET/CT detected extra-axillary lymph node involvement in almost one-third of the patients with stage II-III breast cancer, including regions not evaluable with ultrasound.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / secondary. Carcinoma, Lobular / secondary. Fluorodeoxyglucose F18. Radiopharmaceuticals
  • [MeSH-minor] Adult. Aged. Biopsy, Fine-Needle. Chemotherapy, Adjuvant. Female. Humans. Lymphatic Metastasis / radionuclide imaging. Middle Aged. Positron-Emission Tomography / methods. Prospective Studies

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20719497.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


10. Reitsamer R, Peintinger F, Rettenbacher L, Prokop E: Sentinel lymph node biopsy in breast cancer patients after neoadjuvant chemotherapy. J Surg Oncol; 2003 Oct;84(2):63-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sentinel lymph node biopsy in breast cancer patients after neoadjuvant chemotherapy.
  • The aim of this study was to evaluate the accuracy and the feasibility of SLNB in breast cancer patients who had received preoperative (neoadjuvant) chemotherapy.
  • METHODS: Patients with advanced breast cancer stage II or III who were treated with neoadjuvant chemotherapy were included in the study.
  • Sentinel lymph node (SLN) identification and biopsy was attempted and performed, and axillary lymph node dissection (ALND) was performed in the same surgical procedure after SLNB.
  • The accuracy of SLNB after neoadjuvant chemotherapy is similar to patients with primary surgery.
  • SLNB could be an alternative to ALND in a subgroup of patients after neoadjuvant chemotherapy, and therefore could reduce morbidity due to surgery in those patients.
  • [MeSH-major] Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Lymph Node Excision. Sentinel Lymph Node Biopsy
  • [MeSH-minor] Adult. Aged. Axilla. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / surgery. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / pathology. Carcinoma, Lobular / surgery. Female. Humans. Lymphatic Metastasis. Mastectomy. Middle Aged. Neoadjuvant Therapy. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley-Liss, Inc.
  • (PMID = 14502778.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Reitsamer R, Menzel C, Glueck S, Rettenbacher L, Weismann C, Hutarew G: Sentinel lymph node biopsy is precise after primary systemic therapy in stage II-III breast cancer patients. Ann Surg Oncol; 2010 Oct;17 Suppl 3:286-90
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sentinel lymph node biopsy is precise after primary systemic therapy in stage II-III breast cancer patients.
  • SLNB for axillary staging after primary systemic therapy (PST) is still under discussion because of possibly reduced accuracy, while data are lacking.
  • MATERIALS AND METHODS: A total of 185 breast cancer patients were treated with PST; 160 patients received preoperative chemotherapy, and 25 patients received preoperative endocrine therapy.
  • Thus, 143 of 160 patients with preoperative chemotherapy and 22 of 25 patients with preoperative endocrine therapy were eligible for evaluation.
  • RESULTS: Pathologic complete response rates and breast conserving therapy rates were 15.4 and 78.3% in the preoperative chemotherapy group and 0 and 77.3% in the preoperative endocrine therapy group, respectively.
  • Identification rate, sensitivity, overall accuracy, and false-negative rate were 81.1% (116 of 143), 91.7% (55 of 60), 95.7% (111 of 116), and 8.3% (5 of 60) in the preoperative chemotherapy group and 77.3% (17 of 22), 90.0% (9 of 10), 94.1% (16 of 17), and 10.0% (1 of 10) in the preoperative endocrine therapy group, respectively.
  • DISCUSSION: SLNB after primary systemic therapy is accurate, and the results are comparable to those of primary SLNB.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Lymph Nodes / pathology. Sentinel Lymph Node Biopsy
  • [MeSH-minor] Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / secondary. Carcinoma, Ductal, Breast / surgery. Carcinoma, Intraductal, Noninfiltrating / drug therapy. Carcinoma, Intraductal, Noninfiltrating / secondary. Carcinoma, Intraductal, Noninfiltrating / surgery. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / secondary. Carcinoma, Lobular / surgery. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Mastectomy. Neoplasm Staging. Prognosis. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20853048.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Reitsamer R, Peintinger F, Prokop E, Hitzl W: Pathological complete response rates comparing 3 versus 6 cycles of epidoxorubicin and docetaxel in the neoadjuvant setting of patients with stage II and III breast cancer. Anticancer Drugs; 2005 Sep;16(8):867-70
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathological complete response rates comparing 3 versus 6 cycles of epidoxorubicin and docetaxel in the neoadjuvant setting of patients with stage II and III breast cancer.
  • We conducted a prospective randomized study to compare the results of 3 cycles of epidoxorubicin/docetaxel to 6 cycles of epidoxorubicin/docetaxel prior to surgery in breast cancer patients with clinical stages II and III.
  • Forty-five patients eligible for neoadjuvant chemotherapy were randomly assigned to receive either 3 (group 1) or 6 (group 2) cycles of epidoxorubicin/docetaxel prior to surgery.
  • Chemotherapy consisted of epidoxorubicin 75 mg/m and docetaxel 75 mg/m on day 1 in 3-week cycles.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Neoadjuvant Therapy
  • [MeSH-minor] Adult. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / surgery. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / pathology. Carcinoma, Lobular / surgery. Chemotherapy, Adjuvant. Drug Administration Schedule. Epirubicin / administration & dosage. Epirubicin / analogs & derivatives. Female. Glucuronates / administration & dosage. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Prospective Studies. Receptor, ErbB-2 / metabolism. Remission Induction. Taxoids / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Anticancer Drugs. 2006 Mar;17(3):363
  • (PMID = 16096435.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Glucuronates; 0 / Taxoids; 0 / epidoxorubicin glucuronide; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 15H5577CQD / docetaxel; 3Z8479ZZ5X / Epirubicin; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


13. Schmid P, Krocker J, Schulz CO, Michniewicz K, Dieing A, Eggemann H, Heilmann V, Blohmer JU, Sezer O, Elling D, Possinger K: Primary chemotherapy with gemcitabine, liposomal doxorubicin and docetaxel in patients with locally advanced breast cancer: results of a phase I trial. Anticancer Drugs; 2005 Jan;16(1):21-9
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary chemotherapy with gemcitabine, liposomal doxorubicin and docetaxel in patients with locally advanced breast cancer: results of a phase I trial.
  • The primary objective was to determine the optimal doses for gemcitabine (prolonged infusion), liposomal doxorubicin (Myocet) and docetaxel as primary (neoadjuvant) chemotherapy for locally advanced breast cancer.
  • Patients (n=19) with histologically confirmed stage II or III breast cancer were treated with liposomal doxorubicin (50-60 mg/m2) and docetaxel (60-75 mg/m2) on day 1, and gemcitabine as 4-h infusion (350-400 mg/m2) on day 4.
  • Treatment was repeated every 3 weeks for a maximum of 6 cycles.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Deoxycytidine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / pathology. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / pathology. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Female. Humans. Maximum Tolerated Dose. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Taxoids / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15613900.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; 80168379AG / Doxorubicin; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


14. Mladenovic J, Susnjar S, Gavrilovic D, Borojevic N: Postmastectomy radiotherapy in intermediate risk stage I-II breast cancer patients. J BUON; 2007 Apr-Jun;12(2):215-20
MedlinePlus Health Information. consumer health - Mastectomy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postmastectomy radiotherapy in intermediate risk stage I-II breast cancer patients.
  • PURPOSE: To evaluate the correlation of postmastectomy radiotherapy (PMRT) with local relapse rate, disease-free survival (DFS) and overall survival (OS) in a group of breast cancer (BC) patients at intermediate risk for locoregional relapse (stage I-II with either 1-3 positive axillary nodes, or node-negative grade III BC) treated with radical mastectomy.
  • PATIENTS AND METHODS: We evaluated 482 stage I-II BC patients, with either node-negative grade 3 tumors or with 1-3 positive nodes irrespective of tumor grade, treated with radical mastectomy at our Institute from 1986 to 1994.
  • After mastectomy they received either adjuvant CMF (cyclophosphamide, methotrexate, 5-fluorouracil) chemotherapy (N=172), or adjuvant endocrine therapy (N=310).
  • Postoperative radiotherapy (RT group) to the regional lymph nodes with tumor dose (TD) 48 Gy in 22 fractions was delivered to 199 patients.
  • CONCLUSION: Our results did not show that PMRT significantly influences the incidence of disease relapse, DFS and OS in stage I-II BC patients with intermediate risk for disease relapse.
  • [MeSH-major] Breast Neoplasms / radiotherapy. Carcinoma, Ductal / radiotherapy. Carcinoma, Lobular / radiotherapy. Mastectomy. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17600875.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


15. Von Drygalski A, Tran TB, Messer K, Pu M, Corringham S, Nelson C, Ball ED, Ball ED: Predictors of survival in patients with metastatic breast cancer (MBC) treated with high-dose chemotherapy and autologous stem cell transplantation (HD-ASCT). J Clin Oncol; 2009 May 20;27(15_suppl):e22086

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of survival in patients with metastatic breast cancer (MBC) treated with high-dose chemotherapy and autologous stem cell transplantation (HD-ASCT).
  • : e22086 Background: Individualized care in MBC requires predictors of survival for tailored treatment.
  • METHODS: Age, race, stage at diagnosis, histology, estrogen receptor (ER) and menopausal status, body mass index (BMI) in kg/m2, time to transplant and death, sites of metastasis, disease status prior to and after transplant, and days in hospital were extracted.
  • Brookmeyer & Crowley's 95% confidence intervals, Cox models for predictors of a time-to-event variable and Schoenfeld tests for proportional hazard assumptions were applied.
  • Stratified by ER status, stage at diagnosis was an independent predictor of OS.
  • Patients with stage I at diagnosis were at lowest risk of death when compared to stage II-IV patients with HRs of 2.7 (II vs I CI 1.4-5.2), 4.6 (III vs I CI 2.1-10) and 17 (IV vs I CI 6.1- 47.8).
  • Death risk was increased with BMI ≥ 30 (HR 3.1; CI 1.8-5.4), infiltrating lobular carcinoma (HR 2.5; CI 1.1-5.38) and visceral metastasis (HR 2.3; CI 1.3-4.1).
  • Obesity, late stage at diagnosis, lobular infiltrating histology and visceral metastasis were independent negative predictors of OS.
  • These data may be useful stratification tools for future trials employing HD-ASCT as treatment modality in MBC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963264.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Gonzalez-Angulo AM, Kau SW, Broglio K, Buzdar AU, Theriault RL, Valero V, Sneige N, Frye D, Hortobagyi GN, Cristofanilli M: Invasive lobular carcinoma (ILC) "classic type": Distinct clinical features. J Clin Oncol; 2004 Jul 15;22(14_suppl):663

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive lobular carcinoma (ILC) "classic type": Distinct clinical features.
  • Induction chemotherapy (IC) is used to downstage tumors and facilitate breast conservative surgery.
  • METHODS: 1034 patients (pts) with stage II and III BC participated in six clinical trials using IC at M.D.
  • All pts received anthracycline-based chemotherapy and 246 pts (23.8%) also received a taxane. pCR was defined as no evidence of invasive BC in the breast and axillary lymph nodes.
  • The stratified log-rank test was used to assess differences between OS and RFS among the groups and after adjustments for hormone receptor (HR) status, stage, and pCR.
  • The lobular group tended to be older (med, 53 vs. 47 yrs), have more HR positive tumors, (92% vs. 62%) lower nuclear grade (16% vs. 56% grade 3), and higher stage at diagnosis (10% vs. 0% were IIIB and IIIC).
  • These differences persisted after adjustment for HR status (p=0.02 and 0.03) and stage (both p=0.04).
  • CONCLUSION: ILC is a distinct histological type of breast cancer characterized by better outcome when compared to IDC in spite of the low pCR rate after IC.
  • The role of primary hormonal therapy should be assessed in ILC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28017095.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Dubray P, Durando X, Abrial C, Mouret-Reynier M, Nayl B, Thivat E, Gimbergues P, Achard J, Chollet P, Penault-Llorca F: Preferential pathologic complete response (pCR) in HER-2 positive and triple-negative breast cancer to sequential FEC 100- docetaxel (T) neoadjuvant chemotherapy (NCT) in stage II-III operable breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e11502

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preferential pathologic complete response (pCR) in HER-2 positive and triple-negative breast cancer to sequential FEC 100- docetaxel (T) neoadjuvant chemotherapy (NCT) in stage II-III operable breast cancer.
  • This chemotherapy is currently the reference in the adjuvant setting in France.In PACS 01 trial (Roche et al.
  • METHODS: 101 patients (pts) from February 2005 to September 2008 with stage II-III operable breast cancer received 3 cycles (c) of FEC 100 (epirubicin 100 mg/m<sup>2</sup> + 5-fluorouracil and cyclophosphamide 500mg/m<sup>2</sup>) followed by 3 c of T (100mg/m<sup>2</sup>) every 3 weeks. pCR was defined according to Chevallier's (Am J Clin Oncol, 1993) as level 1 and 2 and to Sataloff's classification (J Am Coll Surg, 1995) as grade A.
  • 83 pts had a ductal, 14 a lobular, 3 ductal and lobular, 1 another carcinoma.
  • 8.9% were grade I SBR, 58.4% grade II SBR, 28.7% grade III SBR and 4% unspecified.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964587.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Shamseddine A, Khalifeh M, Chehal A, Saliba T, Mourad YA, Taher A, Jalloul R, Bitar N, Dandashi A, Abbas J, Geara FB: A clinical phase II study of cisplatinum and vinorelbine (PVn) in advanced breast carcinoma (ABC). Am J Clin Oncol; 2005 Aug;28(4):393-8
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A clinical phase II study of cisplatinum and vinorelbine (PVn) in advanced breast carcinoma (ABC).
  • This report is a pilot study assessing the antitumor efficacy and safety of this regimen as first line therapy for advanced breast cancer patients.
  • METHODS: Thirty-five patients were enrolled: 22 with metastatic breast carcinoma and 13 with locally advanced breast carcinoma (stage III).
  • For the locally advanced breast cancer group, the overall response rate was 92.3% with a median time to disease progression of 26 months (range 25-27).
  • Toxicity was acceptable, and no treatment-related mortality was encountered.
  • CONCLUSIONS: PVn is effective as first line treatment of advanced breast cancer with overall response rate of 64% in metastatic breast cancer and 92.3% in locally advanced breast cancer, and acceptable toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / secondary. Adult. Aged. Bone Neoplasms / secondary. Carcinoma, Ductal / drug therapy. Carcinoma, Ductal / mortality. Carcinoma, Ductal / pathology. Carcinoma, Ductal / secondary. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / mortality. Carcinoma, Lobular / pathology. Carcinoma, Lobular / secondary. Cisplatin / administration & dosage. Female. Follow-Up Studies. Humans. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Pilot Projects. Skin Neoplasms / secondary. Survival Rate. Treatment Outcome. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16062082.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


19. Diaconu C, Chifu C, Iftime C, Iftime I, Miron L, Carasevici E, Ferariu D, Cobzeanu C, Crumpei F: [Bilateral breast cancer (BBC). Considerations on a series of 20 cases]. Rev Med Chir Soc Med Nat Iasi; 2006 Oct-Dec;110(4):867-73
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diagnostic difficulties in the early stage of the contralateral cancer constitute a proven reality even in our cases.
  • The detection of the second metachronous breast tumor was done and evaluated mostly in an more advanced stage than the initial tumours.
  • Most BBC were lobular carcinoma.
  • Adjuvant therapy--chemotherapy, antiestrogens, ovariectomy--do not prevent the appearance of the second tumoral site.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Lobular / diagnosis. Neoplasms, Second Primary / diagnosis

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17438890.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


20. Yoney A, Kucuk A, Unsal M: Male breast cancer: a retrospective analysis. Cancer Radiother; 2009 Apr;13(2):103-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: To evaluate our results in the treatment of male breast cancer patients with respect to local control (LC), overall survival (OS) and possible prognosis factors for survival.
  • Among them, 94.8% had invasive ductal carcinoma (IDC), 2.6% invasive papillary carcinoma (IPC) and 2.6% invasive lobular carcinoma (ILC) and the distribution according to stage was found to be 12.8, 46.2, 30.7 and 10.3% in Stages I, II, III and IV, respectively.
  • Among the patients, 7.7% received radiotherapy (RT) and hormonotherapy (HT), 22.8% received chemotherapy (CT), 61.8% received chemoradiotherapy (CRT) and HT and 7.7% received HT in addition to surgery.
  • In our series, univariate analysis for OS demonstrated statistical significance for lymph node metastases (p=0.00001), stage (p=0.0098) and age (p=0.03); while RT in the treatment modality (p=0.6849), and tumor size (p=0.4439) demonstrated no significance.
  • [MeSH-major] Breast Neoplasms, Male / mortality. Breast Neoplasms, Male / therapy
  • [MeSH-minor] Adult. Age Factors. Aged. Carcinoma, Ductal, Breast / mortality. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / therapy. Carcinoma, Lobular / mortality. Carcinoma, Lobular / pathology. Carcinoma, Lobular / therapy. Carcinoma, Papillary / mortality. Carcinoma, Papillary / pathology. Carcinoma, Papillary / therapy. Disease-Free Survival. Humans. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local. Retrospective Studies

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Breast Cancer, Male.
  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19250851.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  •  go-up   go-down


21. Hui R, Zhang M, Hao XM, Zhang J: [Comparison of tolerance and toxicity of CEF-100 regimen versus CEF-60 regimen as adjuvant therapy for breast cancer]. Zhonghua Zhong Liu Za Zhi; 2007 Nov;29(11):871-4
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparison of tolerance and toxicity of CEF-100 regimen versus CEF-60 regimen as adjuvant therapy for breast cancer].
  • OBJECTIVE: To evaluate tolerance and toxicity of high-dose epirubicin regimen CEF-100 as adjuvant therapy for breast cancer.
  • METHODS: From March 2005 to October 2006, 98 patients with stage I - III a breast cancer were randomly assigned to receive postoperative chemotherapy with CEF-100 regimen (epirubicin 100 mg/m2, dl per 21 days for 6 cycles, n =48) or CEF-60 regimen (epirubicin 60 mg/m2, dl per 21 days for 6 cycles, n = 50).
  • Adverse effects of digestive tract and damage of liver function in CEF-100 group were more severe than that in CEF-60 group (P <0.05), but all adverse effects could be relieved by treatment.
  • There was no death caused by chemotherapy.
  • CONCLUSION: Our data shows that high dose epirubicin-containing CEF regimen is safe and tolerable for postoperative chemotherapy of breast cancer patient, and the adverse effects could be relieved by marrow support and liver-protection therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy. Epirubicin / administration & dosage
  • [MeSH-minor] Adult. Alanine Transaminase / blood. Aspartate Aminotransferases / blood. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / surgery. Chemotherapy, Adjuvant. Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Female. Fluorouracil / adverse effects. Fluorouracil / therapeutic use. Follow-Up Studies. Humans. Leukopenia / chemically induced. Middle Aged. Neutropenia / chemically induced. Vomiting / chemically induced

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18396651.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 8N3DW7272P / Cyclophosphamide; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase; U3P01618RT / Fluorouracil; FEC protocol
  •  go-up   go-down


22. Steger GG, Galid A, Gnant M, Mlineritsch B, Lang A, Tausch C, Rudas M, Greil R, Wenzel C, Singer CF, Haid A, Pöstlberger S, Samonigg H, Luschin-Ebengreuth G, Kwasny W, Klug E, Kubista E, Menzel C, Jakesz R, ABCSG-14: Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14. J Clin Oncol; 2007 May 20;25(15):2012-8
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Preoperative (neoadjuvant) chemotherapy for operable breast cancer downstages tumors initially not suitable for breast-conserving surgery.
  • A pathologic complete response (pCR) to neoadjuvant chemotherapy may be a surrogate for longer overall survival, but this beneficial effect remains to be established.
  • This phase III trial evaluated whether doubling the number of cycles of neoadjuvant treatment increased the pCR rate.
  • PATIENTS AND METHODS: Patients with biopsy-proven breast cancer (T1-4a-c, N+/-, M0; stage I to III) were eligible and randomly assigned to either three or six cycles of epirubicin 75 mg/m2 and docetaxel 75 mg/m2 on day 1 and granulocyte colony-stimulating factor on days 3 through 10 (ED+G), every 21 days.
  • Rates of adverse events were similar, and no patients died on treatment.
  • Thus, six cycles of ED+G should be the standard neoadjuvant treatment for operable breast cancer if this combination is chosen.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Axilla / pathology. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / secondary. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / secondary. Chemotherapy, Adjuvant. Epirubicin / administration & dosage. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Lymphatic Metastasis. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Prospective Studies. Taxoids / administration & dosage

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17513805.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 15H5577CQD / docetaxel; 3Z8479ZZ5X / Epirubicin
  •  go-up   go-down


23. van der Hoeven JJ, Krak NC, Hoekstra OS, Comans EF, Boom RP, van Geldere D, Meijer S, van der Wall E, Buter J, Pinedo HM, Teule GJ, Lammertsma AA: 18F-2-fluoro-2-deoxy-d-glucose positron emission tomography in staging of locally advanced breast cancer. J Clin Oncol; 2004 Apr 1;22(7):1253-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18F-2-fluoro-2-deoxy-d-glucose positron emission tomography in staging of locally advanced breast cancer.
  • PURPOSE: To prospectively evaluate the effect of adding whole-body (18)F-2-fluoro-2-deoxy-d-glucose (FDG) positron emission tomography (PET) to conventional screening for distant metastases in patients with locally advanced breast cancer (LABC).
  • Patients were included if chest x-ray, bone scan, liver ultrasound, or computed tomography scan performed by the referring physician failed to reveal distant metastases.
  • They underwent whole-body FDG PET scanning before therapy.
  • Patients with subsequently proven distant metastases were switched to alternative forms of chemotherapy, hormonal therapy, or both.
  • CONCLUSION: The addition of FDG PET to the standard work-up of patients with LABC may lead to the detection of unexpected distant metastases.
  • This may contribute to a more realistic stratification between patients with true stage III breast cancer and those who are in fact suffering from stage IV disease.
  • Abnormal PET findings should be confirmed to prevent patients from being denied appropriate treatment.
  • [MeSH-major] Breast Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Radiopharmaceuticals. Tomography, Emission-Computed
  • [MeSH-minor] Adenocarcinoma / radiography. Adenocarcinoma / secondary. Adult. Carcinoma, Ductal / radiography. Carcinoma, Ductal / secondary. Carcinoma, Lobular / radiography. Carcinoma, Lobular / secondary. False Negative Reactions. False Positive Reactions. Female. Humans. Middle Aged. Neoplasm Metastasis / diagnosis. Neoplasm Staging. Prospective Studies. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15051773.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


24. d'Annibale M, Piovanello P, Cerasoli V, Campioni N: Liver metastases from breast cancer: the role of surgical treatment. Hepatogastroenterology; 2005 Nov-Dec;52(66):1858-62
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver metastases from breast cancer: the role of surgical treatment.
  • BACKGROUND/AIMS: To evaluate short- and long-term outcomes in the surgical treatment of liver metastases from breast cancer METHODOLOGY: Between 1984 and 1999 we observed 26 patients with secondary liver localization (25 metachronous) from breast cancer.
  • Median age at the time of liver surgery was 56 years (36-76).
  • The 18 patients included: 1 patient at stage 1, 10 at IIA, 6 stage II B and 1 patient at stage IV.
  • Fifteen patients had infiltrating ductal carcinoma, 2 a lobular carcinoma and 1 patient a mixed-component carcinoma.
  • In 9 cases the patients underwent adjuvant chemotherapy (5 of them following postoperative radiotherapy) and in 14 cases Tamoxifen was used.
  • Nine patients died; six patients are still living, 4 of them "disease-free", 2 having advanced metastatic disease, in treatment.
  • The overall 5-year-survival was 25% in patients whose liver metastases developed within 3 years after breast surgery compared with 40% in those ones with metastatic disease diagnosed more than 3 years after.
  • [MeSH-minor] Adult. Aged. Biopsy, Needle. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Palliative Care. Retrospective Studies. Risk Assessment. Survival Analysis. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16334793.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


25. Maughan KL, Lutterbie MA, Ham PS: Treatment of breast cancer. Am Fam Physician; 2010 Jun 1;81(11):1339-46
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of breast cancer.
  • Understanding breast cancer treatment options can help family physicians care for their patients during and after cancer treatment.
  • This article reviews typical treatments based on stage, histology, and biomarkers.
  • Lobular carcinoma in situ does not require treatment.
  • Ductal carcinoma in situ can progress to invasive cancer and is treated with breast-conserving surgery and radiation therapy without further lymph node exploration or systemic therapy.
  • Stages I and II breast cancers are usually treated with breast-conserving surgery and radiation therapy.
  • Radiation therapy following breast-conserving surgery decreases mortality and recurrence.
  • Choice of adjuvant systemic therapy depends on lymph node involvement, hormone receptor status, ERBB2 (formerly HER2 or HER2/neu) overexpression, and patient age and menopausal status.
  • In general, node-positive breast cancer is treated systemically with chemotherapy, endocrine therapy (for hormone receptor-positive cancer), and trastuzumab (for cancer overexpressing ERBB2).
  • Stage III breast cancer typically requires induction chemotherapy to downsize the tumor to facilitate breast-conserving surgery.
  • Inflammatory breast cancer, although considered stage III, is aggressive and requires induction chemotherapy followed by mastectomy, rather than breastconserving surgery, as well as axillary lymph node dissection and chest wall radiation.
  • Prognosis is poor in women with recurrent or metastatic (stage IV) breast cancer, and treatment options must balance benefits in length of life and reduced pain against harms from treatment.
  • [MeSH-major] Breast Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Female. Humans. Mastectomy. Neoplasm Staging. Sentinel Lymph Node Biopsy

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am Fam Physician. 2010 Jun 1;81(11):1330-2 [20521750.001]
  • [CommentIn] Am Fam Physician. 2011 Mar 1;83(5):507; author reply 507 [21391515.001]
  • [CommentIn] Am Fam Physician. 2011 Mar 1;83(5):502-6; author reply 507 [21391514.001]
  • [CommentIn] Am Fam Physician. 2010 Jun 1;81(11):1347-9 [20527363.001]
  • (PMID = 20521754.001).
  • [ISSN] 1532-0650
  • [Journal-full-title] American family physician
  • [ISO-abbreviation] Am Fam Physician
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 63
  •  go-up   go-down


26. Altinyollar H, Dingil G, Berberoglu U: Detection of infraclavicular lymph node metastases using ultrasonography in breast cancer. J Surg Oncol; 2005 Dec 15;92(4):299-303
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of infraclavicular lymph node metastases using ultrasonography in breast cancer.
  • BACKGROUND AND OBJECTIVES: As infraclavicular lymph node metastases is one of the parameters of stage III-C, the diagnostic techniques aiming to identify the metastases of this region have gained importance recently.
  • CONCLUSIONS: Patients who were identified to have infraclavicular lymph node metastases by preoperative ultrasonographic examination should have a relevant treatment plan as they are classified as locally advanced, stage III-C disease.
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Axilla. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / secondary. Carcinoma, Ductal, Breast / ultrasonography. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / secondary. Carcinoma, Lobular / ultrasonography. Clavicle. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Humans. Lymphatic Metastasis. Magnetic Resonance Imaging. Middle Aged. Neoplasm Staging / methods. Predictive Value of Tests. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2005 Wiley-Liss, Inc.
  • (PMID = 16299805.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil; CAF protocol
  •  go-up   go-down






Advertisement